Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomized Dutch Gastric Cancer Group Trial
Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomized Dutch Gastric Cancer Group Trial
复制标题
DOI：
10.1200/jco.2004.08.026
复制
发表时间：
2004-06-01
影响因子：
45.3
通讯作者：
Sasako, M
中科院分区：
文献类型：
--
作者：
Hartgrink, HH;van de Velde, CJH;Sasako, M
目的。胃癌适合淋巴结清扫的程度仍有争议。我们进行了一项随机试验，比较有限（D1）和扩展（D2）淋巴结清扫在发病率、死亡率、长期生存和累积复发风险方面的结果。经过10多年的随访，我们回顾了我们的试验结果。患者和方法。1989年8月至1993年6月间，1078名胃腺癌患者被随机分配进行D1或D2淋巴结清扫。前瞻性地收集数据，并对患者进行了10年以上的随访。共有711例患者（D1组380例，D2组331例）接受治疗。发病率（25% vs 43%）
Purpose. The extent of lymph node dissection appropriate for gastric cancer is still under debate. We have conducted a randomized trial to compare the results of a limited (D1) and extended (D2) lymph node dissection in terms of morbidity, mortality, long-term survival and cumulative risk of relapse. We have reviewed the results of our trial after follow-up of more than 10 years.Patients and Methods. Between August 1989 and June 1993, 1,078 patients with gastric adenocarcinoma were randomly assigned to undergo a D1 or D2 lymph node dissection. Data were collected prospectively, and patients were followed for more than 10 years.Results. A total of 711 patients (380 in the D1 group and 331 in the D2 group) were treated with curative intent. Morbidity (25% v 43%; P